Intarcia Therapeutics, Inc.

Alza Corporation

Other

Durect Corporation

Michael A DesJardin

Pauline C Zamora

Stan Lam

Scott D Lautenbach

Catherine Manya Rohloff

Atul D Ayer

Guohua Chen

Thomas R Alessi

Rupal A Ayer

Andrew S Luk

Paul R Houston

Pedro E De La Serna

David E Edgren

Andrew C Lam

Liang-Chang Dong

Padmaja Shivanand

Kui Liu

Noymi Yam

Padmanabh Bhatt

Phillip R Nixon

Sylvia L Seroff

Patrick S-l Wong

Patrick S L Wong

Stephen A Berry

Pamela J Fereira

Zhongli Ding

James E Matsuura

Beth Hill

Zengji Li

Ekaterina S Zlatkova-Karaslavova

Paula Dennis

Latha Narayanan

Stephen Andrew Berry

Latha Pisharody Narayanan

Gunjan Junnarkar

Scott D Lautenback

John Patrick Carr

An osmotic delivery system is disclosed for delivering an active agent formulation to a fluid environment. The osmotic delivery system typically comprises a reservoir having a lumen that contains the active agent formulation and an osmotic agent formulation and a piston assembly positioned in the lumen to isolate the active agent formulation from the osmotic agent formulation. The piston assembly typically comprises a body constructed and arranged for positioning in the lumen. The body is typically made of a polymeric material that is, for example, resistant to leaching in an organic solvent. In one embodiment, the body is a columnar body having a rim at a distal end thereof for engaging and sealing against a wall of the reservoir and the piston assembly further comprises a spring retained at the distal end of the columnar body for biasing the rim of the columnar body against the wall of the reservoir.

Osmotic delivery systems and piston assemblies for use therein

The present invention is related to materials and methods for forming polymeric delivery vehicles that reduces risk of oxidative degradation of a carried drug and the resulting compositions.

Non-aqueous single phase vehicles and formulations utilizing such vehicles

A nonaqueous, single-phase vehicle that is capable of suspending an active agent. The nonaqueous, single-phase vehicle includes at least one solvent and at least one polymer and is formulated to exhibit phase separation upon contact with an aqueous environment. The at least one solvent may be selected from the group consisting of benzyl benzoate, decanol, ethyl hexyl lactate, and mixtures thereof and the at least one polymer may be selected from the group consisting of a polyester, pyrrolidone, ester of an unsaturated alcohol, ether of an unsaturated alcohol, polyoxyethylenepolyoxypropylene block copolymer, and mixtures thereof. In one embodiment, the at least one solvent is benzyl benzoate and the at least one polymer is polyvinylpyrrolidone. A stable, nonaqueous suspension formulation that includes the nonaqueous, single-phase vehicle and an active agent, and a method of forming the same, are also disclosed.

Solvent/polymer solutions as suspension vehicles

An osmotic delivery system flow modulator includes an outer shell constructed and arranged for positioning in an opening, an inner core inserted in the outer shell, and a fluid channel having a spiral shape defined between the outer shell and the inner core. The fluid channel is adapted for delivery of an active agent formulation from the reservoir of the osmotic delivery system.

Two-piece, internal-channel osmotic delivery system flow modulator

Osmotic drug delivery devices containing suspension formulations comprising particles having active agents and nonaqueous single-phase vehicles

A suspension formulation for therapeutic use includes a non-aqueous, single-phase vehicle exhibiting viscous fluid characteristics and a particle formulation comprising an erythropoietin receptor agonist dispersed in the vehicle.

Stable suspension formulations of erythropoietin receptor agonists

An implantable device includes a reservoir containing a suspension of an interferon in an amount sufficient to provide continuous delivery of the interferon at a therapeutically effective rate of 1 ng/day to 600 &#x3bc;g/day to maintain and achieve therapeutic blood or plasma levels of the interferon throughout a substantial period of the administration period.

Implantable device for continuous delivery of interferon

Growing community of inventors

Sunnyvale, CA, United States of America

Michael A DesJardin